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Abstract
Background: Immune recognition of vascular endothelial cells (EC) has been implicated in allograft rejection, protection
against pathogens, and lymphocyte recruitment. However, EC pervade nearly all tissues and predominate in none,
complicating any direct test of immune recognition. Here, we examined antigen presentation by EC in vivo by testing
immune responses against E. coli β-galactosidase (β-gal) in two lines of transgenic mice that express β-gal exclusively in
their EC. TIE2-lacZ mice express β-gal in all EC and VWF-lacZ mice express β-gal in heart and brain microvascular EC.
Results: Transgenic and congenic wild type FVB mice immunized with β-gal expression vector DNA or β-gal protein
generated high titer, high affinity antisera containing comparable levels of antigen-specific IgG1 and IgG2a isotypes,
suggesting equivalent activation of T helper cell subsets. The immunized transgenic mice remained healthy, their EC
continued to express β-gal, and their blood vessels showed no histological abnormalities. In response to β-gal in vitro,
CD4+ and CD8+ T cells from immunized transgenic and FVB mice proliferated, expressed CD25, and secreted IFN-γ.
Infection with recombinant vaccinia virus encoding β-gal raised equivalent responses in transgenic and FVB mice. Hearts
transplanted from transgenic mice into FVB mice continued to beat and the graft EC continued to express β-gal. These
results suggested immunological ignorance of the transgene encoded EC protein. However, skin transplanted from TIE2-
lacZ onto FVB mice lost β-gal+ EC and the hosts developed β-gal-specific antisera, demonstrating activation of host
immune effector mechanisms. In contrast, skin grafted from TIE2-lacZ onto VWF-lacZ mice retained β-gal+ EC and no
antisera developed, suggesting a tolerant host immune system.
Conclusion: Resting, β-gal+ EC in transgenic mice tolerize specific lymphocytes that would otherwise respond against
β-gal expressed by EC within transplanted skin. We conclude that EC effectively present intracellular "self" proteins to
the immune system. However, antigen presentation by EC does not delete or anergize a large population of specific
lymphocytes that respond to the same protein following conventional immunization with protein or expression vector
DNA. These results clearly demonstrate striking context sensitivity in the immune recognition of EC, a subtlety that must
be better understood in order to treat immune diseases and complications involving the vasculature.
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Background
Endothelial cells (EC) form the inner lining of blood ves-
sels and are therefore uniquely positioned between circu-
lating lymphocytes and peripheral tissues. Vascular EC are
thought to participate in the recruitment of T lymphocytes
from the bloodstream into sites of infection and inflam-
mation [1,2]. After transplantation of vascularized, alloge-
neic tissues, EC are the first graft cells encountered by the
host lymphocytes and may be key initiators and targets of
allograft rejection [3,4]. T cells also protect against intrac-
ellular pathogens that infect EC, such as cytomegalovirus,
Chlamydia pneumoniae, rickettsia and hantavirus. Immune
responses within the blood vessel wall are particularly
important because chronic inflammation can lead to vas-
cular remodeling and the development of arteriosclerosis
[5].
T cell antigen recognition can lead to tolerance or aggres-
sion, depending on the developmental stage of the T cell
and the precise interactions between the T cell and the
antigen presenting cell (APC). T cell antigen receptors rec-
ognize specific peptides bound to MHC molecules on the
surface of the APC. Professional APC provide certain addi-
tional activities, collectively termed costimulation, that
regulate and strengthen T cell responses. Cell surface mol-
ecules and soluble proteins (chemokines, cytokines, and
lymphokines) mediate costimulation. Professional APC
express CD80 (B7-1) and related molecules, which act
through CD28-related molecules on T cells. Professional
APC also express CD40, which acts through CD154
(CD40 ligand) and is an essential mediator of collabora-
tion between T cells [6-8].
EC have been termed "semiprofessional" APC because
they costimulate certain T cell responses in vitro and
because they are thought to stimulate alloresponses in vivo
[9-13]. EC cultured from different vascular beds can act as
APC  in vitro. For example, EC cultured from human
umbilical veins (HUVEC), pulmonary arteries, iliac arter-
ies and veins, and murine lung EC all costimulated T cells
treated with mitogens, generating stronger proliferation
and IL-2 secretion [9,14-20]. In contrast, vascular smooth
muscle cells do not provide costimulation [20]. Human
EC express CD40, CD58 (LFA-3), CD134 (OX40) ligand
and ICOS ligand, which can contribute to T cell activation
in vitro [21-23]. HUVEC do not express CD80 and they
cannot stimulate naïve T cells in vitro [24]. Although
murine lung microvascular EC do express CD80, they cos-
timulated only memory T cells in vitro [25]. Mouse liver
sinusoidal EC express CD80 and other costimulatory mol-
ecules but they are reported to induce antigen specific tol-
erance  in vitro [26]. In contrast, murine aortic EC can
stimulate in vitro naive T cells expressing alloreactive anti-
gen receptor transgenes [27]. Thus, EC costimulation
properties in vitro may differ depending upon the antigen,
the species, the maturity of the T cell, and the vascular bed
of origin.
EC activities as APC in vitro may be poor indicators of their
activities in vivo because cells change upon isolation and
culture. For example, although human EC strongly
express MHC class I and class II molecules in vivo, MHC
class I expression is reduced and class II expression is lost
in vitro [28,29]. Murine EC also express elevated levels of
MHC class I molecules in vivo, which is dependent on IFN-
γ [30]. Static cocultures of leukocytes and EC may be mis-
leading because shear forces promote the migration of
lymphocytes and other leukocytes across the endothelium
[31-33]. In addition, efficient T cell activation can require
transient, not prolonged, stimulation by APC [34]. Thus,
gene expression and cellular interactions are profoundly
altered by culture conditions in vitro.
Transgenic mice are ideal for investigating antigen presen-
tation by particular cell types. Cells remain in their physi-
ological setting and transgene expression avoids the
inflammation caused by other means of gene targeting,
such as transfection or infection. Tissue specific gene pro-
moters have been used to test the immune consequences
of a restricted protein expression. Transgene expression
within the primary lymphoid organs usually leads to tol-
erance. For example, lymphocytes specific for E. coli β-
galactosidase (β-gal) were tolerized in transgenic mice
expressing β-gal under the control of a B lymphocyte pro-
moter [35]. When these mice were immunized with β-gal
protein, only low titer, low affinity antisera were raised. In
contrast, astrocytes or vascular smooth muscle cells
expressing β-gal were initially ignored [36,37]. However,
β-gal immunization of these mice induced a strong
humoral and cellular response that led to lymphocytic
infiltrates and pathology. Miller and colleagues noted that
EC in an intact vasculature usually shield circulating lym-
phocytes from peripheral transgene expression [38].
Immune responses against transgene-encoded antigens
expressed in the periphery often occurred only after dis-
ruption of the tissue and vasculature exposed the paren-
chymal cells to circulating lymphocytes [39].
To investigate the role of EC in presenting antigens in vivo,
we tested the immune responses against β-gal in two dif-
ferent lines of transgenic mice that express β-gal exclu-
sively in their EC. In VWF-lacZ mice, a portion of the
promoter and the first intron of the gene encoding von
Willebrand factor (VWF), a procoagulant EC protein,
drives the expression of β-gal in microvascular EC of the
heart and brain [40]. In TIE2-lacZ mice, a portion of the
promoter and first intron of the gene encoding TIE2, the
receptor for the vascular differentiation factor angiopoie-
tin-1, drives the expression of β-gal in many EC in all
organs [41]. We compared the responses of these trans-BMC Immunology 2004, 5 http://www.biomedcentral.com/1471-2172/5/5
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genic mice to wild type, congenic FVB mice following β-
gal immunization and tissue transplantation. We found
that transgenic mice can mount strong, β-gal-specific cel-
lular and humoral responses without causing any detecta-
ble injury to the endogenous β-gal+ EC. Transplanted skin,
but not hearts, containing β-gal+ EC triggered β-gal-spe-
cific immune responses in FVB mice although both TIE2-
lacZ and VWF-lacZ mice accepted the grafts. The failure of
the VWF-lacZ and TIE2-lacZ mice to respond against the
β-gal+ EC in TIE2-lacZ skin demonstrates that the immune
system recognizes and accommodates proteins presented
by EC.
Results
Transgenic mice respond to immunization with β-gal
To determine the state of β-gal specific lymphocytes in
transgenic mice expressing β-gal in their vascular EC,
VWF-lacZ transgenic and wild type mice were immunized
with a β-gal expression vector DNA using a gene gun.
DNA immunization can induce both humoral and cellu-
lar responses [42-44] and B lymphocytes require specific T
cell help to form a high titer antiserum against β-gal [45].
Thus, antiserum titers demonstrated the activity of antigen
specific B cells and also provided valuable surrogate mark-
ers for assessing the state of antigen specific T cell popula-
tions. The antiserum titer and antibody composition were
determined by an Ig isotype specific ELISA for antibodies
to β-gal.
Immunization raised high titer, β-gal specific antisera in
both transgenic VWF-lacZ and congenic, wild type FVB
mice (Figure 1A, filled symbols). Ig isotypes characteristic
of both Th1-like responses (IgG2a) and Th2-like
responses (IgG1) were detected at equivalent levels in
transgenic and wild type mice (Figure 1A). Serum col-
lected from these mice before immunization (preim-
mune) or from mice immunized with a control
expression vector (CMV-GFP) did not contain β-gal spe-
cific antibodies (open symbols, Figure 1A), demonstrat-
ing that the antisera were formed in response to the
immunization. Both VWF-lacZ and FVB mice generated
primary antisera that were much stronger than sera from
non-immune mice and the secondary responses were
even stronger, demonstrating maturation of the immune
response in both transgenic and wild type mice (Figure
1B). Similarly, immunized TIE2-lacZ transgenic mice also
generated strong antisera against β-gal (Figure 1C). Thus,
expression of β-gal in the EC of these transgenic mice did
not appear to alter their immune responses against β-gal.
B lymphocytes secreting high affinity antibodies can be
the most susceptible to tolerance induction [35]. To com-
pare the affinities of the β-gal specific antisera from trans-
genic and wild type mice, we incubated the sera with
soluble  β-gal before adding them to the coated wells.
Once bound to antigen, high affinity antibodies are less
likely to dissociate and bind the plated antigen, providing
a good measure of affinity [46]. Equivalent levels of solu-
ble  β-gal inhibited sera from wild type and transgenic
mice, suggesting that they have equivalent affinities for β-
gal (Figure 1D). Plate binding was halved (IC50) between
10–100 pM free β-gal, demonstrating the generation of
high affinity antisera in both strains. Surface plasmon res-
onance assays also suggested equivalent antibody affini-
ties in wild type and transgenic mouse sera (Biacore, data
not shown).
We also compared immune responses to immunization
with β-gal protein. Transgenic and wild-type mice were
immunized with β-gal protein emulsified in complete Fre-
und's adjuvant (CFA). Both strains of transgenic mice and
the wild type mice responded with high titer antisera con-
taining both IgG1 and IgG2a isotype antibodies (Figure
2).
Specific T cells in TIE2-lacZ and VWF-lacZ mice respond 
against "self" β-gal
To analyze directly the T cell responses in transgenic mice,
we measured the responses of lymph node T cells from
immunized mice in vitro. Proliferation was measured by
tritiated ([3H]) thymidine incorporation. The expansion
of CD4+ (helper) and CD8+ (cytotoxic) T cell populations
was measured by immunostaining and FACS analysis.
Activated T cells were detected by their expression of
CD25 (IL-2 growth factor receptor) and effector functions
were assessed by measuring IFN-γ secretion.
In cultures that received β-gal protein, both CD4+ and
CD8+ T cells from wild type and transgenic mice were acti-
vated (CD25+) on day 4 in vitro (Figure 3A). Cultures that
received β-gal protein antigen contained many more cells
than those that did not. We compared the kinetics of acti-
vation in the three mouse strains. The data compiled from
several independent experiments revealed that activation
of CD4+ and CD8+ T cells from transgenic and FVB mice
peaked between days 4 and 6 (Figure 3B). To determine
the antigen presentation pathways, monoclonal antibod-
ies that bind FVB (H-2q) MHC class I or class II molecules
were added at the beginning of the culture (34-5-3S or 15-
1-5P hybridoma supernatants, ATCC). Each antibody par-
tially blocked T cell proliferation, suggesting that β-gal
peptides are presented by both MHC class I and class II
molecules (data not shown).
Tolerance may be most evident in the T cell populations
with highest avidity for the antigen [47]. T cell avidity can
be estimated by reducing the antigen dose, which limits
antigen more rapidly for lower avidity T cells. T cells from
transgenic and FVB mice showed equivalent dose-
response relationships (Figure 3C), suggesting that T cellsBMC Immunology 2004, 5 http://www.biomedcentral.com/1471-2172/5/5
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Genetic immunization with a β-gal expression vector induces strong humoral responses in wild type mice (FVB) and transgenic  mice (VWF-lacZ and TIE2-lacZ) that express β-gal in their endothelial cells Figure 1
Genetic immunization with a β-gal expression vector induces strong humoral responses in wild type mice 
(FVB) and transgenic mice (VWF-lacZ and TIE2-lacZ) that express β-gal in their endothelial cells A. Equivalent 
β-gal specific antisera are generated in FVB and VWF-lacZ mice. ELISAs were performed on antisera from mice immunized 6 
weeks earlier with a gene gun. Closed markers represent sera from mice immunized with the expression vector CMV-β gal. 
Open markers represent preimmune sera (VWF-lacZ) or sera from mice immunized with a control expression vector (CMV-
GFP, FVB). Similar results were obtained in two independent experiments. B. The humoral response matures in wild type and 
transgenic mice. Titers of antibodies in control sera (0) and sera from mice immunized once (1') or twice (2') with the CMV-β-
gal expression vector DNA are shown. Similar results were obtained in two independent experiments. C. TIE2-lacZ mice 
respond against β-gal. Antisera of wild type (FVB) and TIE2-lacZ mice immunized once 6 weeks previously are shown. Closed 
symbols represent sera assayed on plates coated with β-gal, open symbols represent assays on control, BSA-coated plates. 
Similar results were obtained in two independent experiments. Titers of sera from pre- or un-immunized mice were <10-2 (not 
shown). D. Soluble β-gal competes for antibodies in sera from FVB and transgenic mice equivalently. Sera from immunized and 
boosted mice were mixed with soluble β-gal at the concentrations indicated and incubated overnight at 4°C. Free antibodies 
were then detected by adding the mixture to β-gal coated wells.
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with similar avidities respond against β-gal in wild type
and transgenic mice.
We next tested the effector functions of β-gal specific T
cells. IFN-γ is an important antiviral cytokine produced by
T cells. Recently, IFN-γ was shown to also induce blood
vessel remodeling in the absence of leukocytes, suggesting
that IFN-γ may link pathological changes in blood vessels
to immune responses occurring within the vessel wall
[48]. To test IFN-γ secretion, lymph node cells were res-
timulated immediately ex vivo with  β-gal. Equivalent
amounts of IFN-γ induced by β-gal were detected in the
supernatants of cultured lymph node cells from trans-
genic and wild type mice (Figure 3D). This was true at all
times after the initiation of culture, with the peak accumu-
lation occurring between days 2 and 3. However, substan-
tial variation was observed in the responses of the TIE2-
lacZ mice. Whereas lymph node cells from FVB and trans-
genic VWF-lacZ mice responded to β-gal by secreting
equivalent amounts of IFN-γ in 5 out of 5 experiments,
lymph node cells from TIE2-lacZ mice produced equiva-
lent or higher amounts of IFN-γ twice, lower amounts
twice, and were unresponsive once (not shown).
Although the reason for variation in the TIE2-lacZ
responses is uncertain, it is clear that effector T cell popu-
lations from the transgenic mice are capable of respond-
ing normally following immunization with β-gal.
Transgenic mice respond to infection with vaccinia virus 
encoding β-gal
It was possible that conventional immunization protocols
did not efficiently induce mature T cells capable of
responding aggressively against intracellular proteins.
Immune responses against microbial products can pro-
duce autoimmunity when they cross-react with self-pro-
teins [49]. We attempted to initiate self-reactivity by
infecting transgenic mice with a recombinant vaccinia
virus encoding β-gal (β-gal-VV).
Wild type FVB, VWF-lacZ, and TIE2-lacZ mice all
responded to β-gal-VV infection with antisera specific for
β-gal (8 mice from each strain, 2 independent experi-
ments, data not shown). Lymphocyte responses in a small
number of mice were also tested ex vivo. One week after
infection, splenocytes from wild type and transgenic mice
proliferated and secreted IFN-γ in response to cells
infected with β-gal-VV and cells expressing a β-gal trans-
gene but not uninfected cells alone (data not shown). All
of the mice remained healthy for over two months post-
infection.
EC continue to express β-gal in immune, transgenic mice
Transgenic mice remained apparently healthy for over 9
months after immunization with DNA or protein. Antise-
rum specific for β-gal would not be expected to bind EC in
transgenic mice because the enzyme is expressed in the
cytoplasm and not on the cell surface. However, specific T
cells could perhaps respond against β-gal peptides pre-
sented on EC. To detect any immune effects on the vascu-
lature, organs were harvested, fixed and sectioned, and
blood vessels were stained and analyzed by morphome-
try. The heart (left ventricle), liver, lung, and spleen, the
infrarenal aorta, ascending aorta, coronary artery, carotid
artery, and iliac artery were examined in cross section.
There were no histological abnormalities. No changes
were observed in the areas of the lumen, intima, media or
vessel (defined as within the external elastic lamina) of
any of the large vessels examined (data not shown).
It was possible that mice reduced their expression of the
lacZ transgene upon mounting an immune response. For
example, transgenic mice expressing hepatitis B antigens
were shown to reduce their expression of the viral trans-
genes upon infection with virus [50].
To compare overall lacZ expression in immunized and
unimmunized mice, whole tissues were stained with the
chromogenic β-gal substrate 5-bromo-4-chloro-3-indolyl-
β-D-galactopyranoside (X-gal). Cardiac EC expressed
Immunization with β-gal protein in adjuvant raises strong  antibody responses in wild type (FVB) and transgenic (VWF- lacZ and TIE2-lacZ) mice Figure 2
Immunization with β-gal protein in adjuvant raises 
strong antibody responses in wild type (FVB) and 
transgenic (VWF-lacZ and TIE2-lacZ) mice. Serum 
samples were taken 2 weeks after boosting with soluble β-gal 
and specific antibodies were measured by ELISA. Closed 
symbols represent sera assayed on β-gal coated plates and 
open symbols represent sera assayed on control, BSA-coated 
plates.
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T cells from immunized FVB and transgenic VWF-lacZ and TIE2-lacZ mice respond to β-gal in vitro Figure 3
T cells from immunized FVB and transgenic VWF-lacZ and TIE2-lacZ mice respond to β-gal in vitro. A. CD4+ 
and CD8+ lymph node T cells proliferate and express IL-2 receptors (CD25+) in response to β-gal. Representative FACS pro-
files are shown. Lymph node cells were obtained from mice 7 days after in vivo priming in all the experiments shown. Lymph 
node cells (2 × 105) were cultured in flat bottom wells and stained for CD4, CD8, and CD25 on day 4. The histograms repre-
sent CD25 expression in cultures receiving β-gal (thick line) or not (thin line). B. CD25+ lymphocyte populations expand in cul-
tures of lymph node cells from FVB and transgenic mice. The results of three independent FACS experiments are shown, each 
represented with a different symbol, and the mean response at each time is indicated with a dash. For the stimulation indices, 
the background proliferation of cultures receiving no addition or ovalbumin additions were averaged. C. Wild type and trans-
genic T cells display equivalent avidity for β-gal. Lymph node cells (105) were cultured with irradiated (1500 R) splenocytes 
(106) in flat bottom wells with the indicated concentrations of β-gal. Results for day 4 are shown. Similar results were obtained 
in more than 4 independent dose-response proliferation assays. D. FVB and transgenic T cells secrete IFN-γ in response to β-
gal. Lymph node cells (2 × 105) were cultured in round bottom wells with β-gal (closed squares) or without (open squares). 
Culture superantants were recovered at the times indicated, one sample per culture, three cultures per point, and IFN-γ was 
measured by ELISA.
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equivalent, easily detectable amounts of β-gal in immu-
nized and unimmunized TIE2-lacZ and VWF-lacZ mice
but not in control FVB mice (Figure 4A). Dermal EC also
continued to express β-gal at comparable levels in immu-
nized and unimmunized TIE2-lacZ mice (Figure 4B).
Therefore, EC continued to express β-gal despite the
strong humoral and cellular immune responses specific
for β-gal.
Transgenic heart transplants are accepted and retain β-
gal+ EC
Transplantation offers an in vivo test of immune recogni-
tion. To test immune responses against cardiac EC
expressing β-gal, we performed heterotopic heart trans-
plants from TIE2-lacZ or VWF-lacZ mice into wild type
FVB mice. Graft survival was monitored by palpation and
the strength of the graft heartbeat was noted.
In three series of transplantations, only 9 out of 35 trans-
planted hearts or hosts did not survive the procedure, fail-
ing within 1 week for technical reasons. Nearly all
transgenic donor hearts that survived 1 week continued to
beat for over 60 days after transplantation into FVB mice
(11 out of 12 TIE2-lacZ; 10 out of 12 VWF-lacZ). Two con-
trol FVB transplants showed similar graft survival. β-gal
specific antisera were not induced in FVB hosts of trans-
genic hearts (data not shown). Transgenic grafts survived
even when the recipients were sensitized before transplan-
tation by TIE2-lacZ skin graft or by immunization with β-
gal protein in adjuvant (data not shown).
It was possible that the donor EC were replaced or
stopped making β-gal. To test β-gal expression in the
donor EC, hearts from long-term graft survivors were har-
vested and stained for β-gal expression. The vascular EC
within the donor hearts continued to express β-gal (Figure
5) and the graft vessels were histologically normal (data
not shown). Therefore, the transplanted hearts survived
despite the continued expression of β-gal by their EC.
β-gal+ EC in skin grafts trigger immunity and are cleared 
from wild-type FVB but not transgenic VWF-lacZ hosts
Skin grafting is a more rigorous test of immunological tol-
erance, capable of detecting very small differences
between host and donor tissues. We performed full
thickness skin transplants between TIE2-lacZ mice and
wild type FVB mice. Full thickness grafts included the
blood vessels underlying the muscle layer.
Skin grafts between transgenic TIE2-lacZ and wild type
FVB mice appeared to survive equivalently on both hosts
(5 separate experiments, totaling over 20 host mice of
each strain). When skin grafts were reversed before place-
ment and stapling, the direction of the re-grown fur also
indicated that both hosts accepted the grafts. However, β-
gal specific antibodies were detected in the serum of FVB
mice engrafted with TIE2-lacZ skin (Figure 6A, represent-
ative of 5 separate experiments). The antibodies were
largely of the IgG2a isotype, which predominate in cellu-
lar, Th1-mediated responses. No β-gal specific antibodies
were detected in TIE2-lacZ mice engrafted with FVB skin
or TIE2-lacZ mice engrafted with TIE2-lacZ skin.
To test whether β-gal expression by cardiac EC had any
effect on the host immune response, VWF-lacZ mice were
grafted with TIE2-lacZ skin. In 3 separate experiments, all
but one of the control FVB mice (7 out of 8) and none of
the VWF-lacZ mice (8 out of 8) developed antibodies, sug-
gesting the VWF-lacZ mice accepted the β-gal+ EC in the
donor TIE2-lacZ skin grafts (Figure 6B). In addition, the β-
gal expression by EC within the skin grafts was analyzed
by X-gal staining. All TIE2-lacZ skin grafts transplanted
onto VWF-lacZ mice contained many β-gal+ EC whereas
virtually no β-gal+ EC were observed in the grafts trans-
planted onto FVB mice (Figure 6C). The organization of
the β-gal+ vessels within the TIE2-lacZ graft was disrupted,
suggesting that the dermal vasculature had undergone
remodeling but not replacement during engraftment (Fig-
ure 6C, compare TIE2-lacZ donor vs. VWF-lacZ host). The
continued presence of β-gal+ EC in grafts on VWF-lacZ
mice demonstrates that EC normally remain in the graft
and suggests that EC were cleared from the grafts on FVB
mice, probably by the host immune response.
We also tested the effect of EC activation on lymphocyte
recognition by denuding endothelium from femoral arter-
ies by wire injury in TIE2-lacZ mice immunized against β-
gal. Vessels were allowed to repair for 4 weeks and then
they were analyzed by morphometry and staining for β-
gal. The EC within the repaired vessels continued to
express β-gal and there were no changes in the intimal,
medial or overall vessel areas (Jun Yu and William Sessa,
personal communication), suggesting that activated EC in
large vessels are not able to activate specific T cells in vivo.
Discussion
Transgenic mice have been widely used to analyze
immune recognition of particular cell types in vivo
(reviewed in [51]). Previous studies have found that trans-
genes expressed in the periphery were usually ignored
initially, perhaps in part because naïve T cells do not cir-
culate through peripheral tissues [36,37]. Other studies
showed that autoimmunity could result if lymphocytes
specific for transgene-encoded proteins trafficked into the
parenchyma following either tissue disruption or immu-
nization [38,39]. Similarly, immunization with self pro-
teins in adjuvant can produce autoimmunity against
antigens that are normally sequestered from the naive
immune system (e.g., thyroglobulin and thyroiditis, mye-
lin basic protein and encephalopathy).BMC Immunology 2004, 5 http://www.biomedcentral.com/1471-2172/5/5
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EC continue to express β-gal in transgenic VWF-lacZ and TIE2-lacZ mice mounting strong immune responses against β-gal Figure 4
EC continue to express β-gal in transgenic VWF-lacZ and TIE2-lacZ mice mounting strong immune responses 
against β-gal. A. EC in cardiac vessels of immunized, transgenic mice continue to make β-gal. Control, unimmunized mice and 
mice immunized and boosted with β-gal protein were sacrificed and their hearts were harvested and stained with X-gal. Repre-
sentative fields are shown. Similar results were obtained in four independent experiments, two analyzing mice immunized with 
β-gal protein and two analyzing mice immunized with β-gal expression vectors. B. Dermal EC of immunized, transgenic TIE2-
lacZ mice continue to express β-gal. Mice were sacrificed and full-thickness portions of their skins were stained with X-gal. The 
underside is shown. Unimmunized TIE2-lacZ mice expressed equivalent levels of β-gal, as assessed by X-gal staining (not 
shown).
A. Heart Tissue FVB VWF-lacZ Tie2-lacZ
Not
Immunized
0.5 mm
Immunized
B. Skin tissue, Immunized mice
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1 mm
VWF-lacZ Tie2-lacZBMC Immunology 2004, 5 http://www.biomedcentral.com/1471-2172/5/5
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EC have been called "semiprofessional" APC because they
do not express certain costimulatory molecules yet they
enhance T cell responses in vitro and are thought to stim-
ulate alloresponses in vivo [9-12,52]. To determine the
ability of EC to act as APC in vivo, we analyzed the behav-
ior of β-gal-specific lymphocytes in transgenic mice that
express β-gal exclusively in their EC. We reasoned that if
EC normally presented antigen to circulating T cells, then
β-gal-specific T cells would be anergized (rendered unre-
sponsive) or deleted to maintain self-tolerance. In this
case, immune responses against β-gal would be reduced
or absent. Alternatively, if EC did not normally act as APC,
then specific T cells would be responsive and help to gen-
erate strong immune responses. Once activated by profes-
sional APC, memory T cells might be subsequently
stimulated by, and target, EC expressing the transgene.
Our results indicate that EC are capable of presenting anti-
gen, but this presentation does not result in anergy or
deletion of β-gal-specific T cells, and does not prevent the
generation of a strong immune response.
VWF-lacZ mice and TIE2-lacZ immunized with β-gal pro-
tein,  β-gal-DNA, or vaccinia virus expressing β-gal
mounted strong humoral and cellular immune responses
against β-gal but showed no evidence of EC damage (Fig-
ures 1, 2, 3, 4). One definition of tolerance is the failure to
mount a destructive immune response (Ehrlich's "horror
autotoxicus", [53,54]). By this definition, these transgenic
mice are tolerant of β-gal, despite generating specific antis-
era and T cells, because they do not appear to injure their
own EC that express the antigen. Alternatively, tolerance
has also been defined as unresponsiveness to an (other-
wise) immunogenic antigen [54]. By this definition, toler-
ance is not induced because a strong immune response is
detected. While the strong β-gal specific antisera would
not be expected to damage EC expressing intracellular β-
gal [54], it is unclear why the activation of β-gal specific T
cells did not lead to vascular pathology.
One possibility, that the β-gal expressed by EC is ignored
by the immune system, is not supported by the findings
that skin containing β-gal expressing EC triggered an anti-
Transplanted hearts from transgenic mice are tolerated and continue to express β-gal Figure 5
Transplanted hearts from transgenic mice are tolerated and continue to express β-gal. Heterotopic transplants 
were harvested 3 months after transplantation and stained with X-gal. Similar results were obtained in 2 additional 
experiments.
Hearts
Host FVB Donor VWF-lacZBMC Immunology 2004, 5 http://www.biomedcentral.com/1471-2172/5/5
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β-gal+ EC trigger immune responses and are cleared from TIE2-lacZ skin grafts onto wild type FVB but not VWF-lacZ hosts Figure 6
β-gal+ EC trigger immune responses and are cleared from TIE2-lacZ skin grafts onto wild type FVB but not 
VWF-lacZ hosts. A. ELISA of sera from reciprocal donor-host skin transplants detects β-gal specific antibodies in FVB but 
not TIE2-lacZ hosts. Similar results were obtained in 3 separate experiments, in which 7 out of 8 wild type mice generated 
strong IgG2a isotype antibodies to β-gal following TIE2-lacZ skin grafts. B. VWF-lacZ mice do not raise β-gal-specific antisera 
following grafting with TIE2-lacZ skin. Grafting and antisera were analyzed as described above.C. EC expressing β-gal are 
cleared from TIE2-lacZ skin grafts onto host wild type FVB but not VWF-lacZ mice. Photomicrographs of the underside of X-
gal stained donor TIE2-lacZ skin and TIE2-lacZ skin grafts from FVB or VWF-lacZ hosts are shown.
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gen-specific immune response when transplanted onto
wild type, but not TIE2-lacZ mice (Figure 6). In addition,
the inability of VWF transgenic mice to respond to these
skin grafts provides evidence that β-gal expressed by heart
and or brain EC is not ignored, but is presented, albeit in
a manner that does not render the host completely unre-
sponsive. It is possible that the inflamed setting of the skin
graft activated graft EC to become better APC or that dead
EC were cross presented by professional APC. However,
the observation that VWF-lacZ mice did not raise immune
responses against β-gal+ EC in TIE2-lacZ skin grafts (Figure
6B) strongly suggests that specific lymphocytes directly
recognize and are rendered unresponsive by resting,
endogenous, β-gal+ cardiac EC within the intact vascula-
ture. Proinflammatory stimuli present in the skin grafts
were not able to cause VWF-lacZ mice to generate β-gal-
specific antibody responses. Furthermore, even though EC
at sites of inflammation adopt an activated phenotype
and may be better APC, T cells activated by professional
APC in the course of an immune response in vivo should
be able to recognize quiescent EC. For example, brain EC
and HUVEC are good CTL targets in vitro despite being
inefficient APC [55-57].
A second explanation for the lack of vascular pathology in
the presence of circulating β-gal-specific T cells is that EC
in transgenic mice could express a slightly different form
of β-gal than the protein or DNA-encoded forms we used
for immunization. We sequenced the PCR-amplified lacZ
gene from both transgenic strains and found it is identical
to the E. coli gene contained in the CMV-lacZ expression
construct. Cell-specific post-translational modifications
could add or mask epitopes. However, the antibody assays
and the T cell proliferation assays demonstrated that
many epitopes are common between the purified protein
and the forms encoded by the transgenes or the expres-
sion vector.
A third possibility is that the destructive immune response
is actively controlled by regulatory mechanisms. Others
have shown that cytotoxic T cells (CTL) specific for trans-
gene-encoded cytoplasmic proteins expressed in periph-
eral tissues could be generated from tolerant mice only
after extended culture in vitro [38,58-61]. No killing was
detectable in vivo when CTL were adoptively transferred to
transgenic animals. Such dominant tolerance of many
peripheral proteins appears to be established and main-
tained by regulatory or suppressor T cells, which have
been demonstrated in a number of systems in vivo
(reviewed in [62]). CTLA-4+ T cells can suppress self-reac-
tivity following weak immunization with a transgene-
encoded protein [63]. To examine the possibility that
aggressive T cells responded against β-gal in wild-type FVB
mice but were controlled in the transgenic mice, we adop-
tively transferred lymphocytes from immunized, wild
type FVB mice into transgenic mice. Immunization was
performed with protein in adjuvant or by skin grafting.
The adoptive VWF-lacZ and TIE2-lacZ hosts remained
healthy for more than 6 months following the transfer of
primed spleen cells or lymph node cells (data not shown),
suggesting that either aggressive lymphocytes were not
primed in wild type mice or their activity was controlled
in transgenic mice.
Central tolerance is caused by protein expression within
the central immune system and lymphoid organs, princi-
pally within the thymic epithelium, usually resulting in
complete unresponsiveness against the protein [35]. The
investigators who generated the VWF-lacZ and TIE2-lacZ
mice thoroughly examined β-gal expression patterns and
concluded that in post-embryonic mice, vascular EC alone
expressed β-gal [40,41]. We could not detect β-gal mRNA
in the thymus of VWF-lacZ mice when we analyzed
expression by reverse-transcription, PCR (RT-PCR),
although we could easily detect β-gal mRNA in VWF-lacZ
hearts and TIE2-lacZ thymus tissues (not shown). How-
ever, it is possible that undetectable levels of expression in
the thymus or elsewhere in VWF-lacZ and TIE2-lacZ mice
cause an incomplete central tolerance that is responsible
for their acceptance of TIE2-lacZ skin.
Immune tolerance is usually a consequence of T cell toler-
ance, which is achieved through ignorance, clonal anergy,
clonal exhaustion, suppression, or a combination of these
mechanisms [58,64,65]. The restricted circulation of
naïve T cells through only the lymphoid organs helps
maintain ignorance of many peripheral proteins. How-
ever,  any  circulation would expose T cells to antigens
expressed by vascular EC. Unlike some cell types such as
neurons, which express almost no MHC proteins, murine
and human EC express easily detectable levels of MHC
class I proteins in vivo [29,30]. The EC in these transgenic
mice also express significant amounts of β-gal (Figure 4),
suggesting that MHC-peptide complexes are relatively
abundant. Very few MHC-peptide complexes are neces-
sary to trigger mature T cells [66]. Tolerance can result
from anergy caused by inadequate costimulation [67].
However, many β-gal specific T cells in the TIE2-lacZ mice
proliferate in vitro after priming in vivo (Figure 3), demon-
strating that they were not anergized in the many different
vascular beds containing the β-gal+ EC.
Conclusions
We conclude that EC effectively present intracellular "self"
proteins to the immune system, resulting in a form of tol-
erance. However, antigens presented by EC do not aner-
gize naïve lymphocytes that are activated by conventional
immunization protocols or by vaccination. EC are also
not effective targets of these lymphocytes activated by
conventional immunization. Restricted antigen presenta-BMC Immunology 2004, 5 http://www.biomedcentral.com/1471-2172/5/5
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tion by EC may contribute to the inability of the immune
response to clear certain chronic infections by pathogens
that target EC, such as Chlamydia pneumonia and
cytomegalovirus.
Methods
Mice
VWF-lacZ transgenic mice were provided for this study by
Dr. William Aird (Beth Israel Deaconess Medical Center,
Boston) [40]. TIE2-lacZ transgenic mice were generated by
Sato and colleagues [41] and purchased from the Jackson
Laboratories (Bar Harbor, ME). Both transgenic strains
were generated and maintained on the FVB background.
The lines were maintained by backcrossing hemizygous
transgenic mice to FVB/NJ mice (Jackson Laboratories).
Transgenic offspring were identified from ear punches at
approximately 6 weeks of age. The punches were digested
(100 µl, 10 µg proteinase K, 10 mM KCl, 10 mM Tris pH
8, 2.5 mM MgCl2, 0.45% NP-40, 0.45% Tween-20) for 3
h at 55°C then heated for 10 min. at 95°C. PCR was per-
formed using 1 µl of the digest with primers for lacZ
(Bgal.51: GCGTTGGCAATTTAACCG and Bgal.31: TGG-
TAATGGTAGCGACCG, each at 0.5 µM) and a control
sequence tagged site (STS) from the X chromosome
(M37335, each primer at 0.1 µM). The cycling conditions
were: 1 min at 94°C, then 30 cycles of 30 s at 94°C, 30 s
at 53°C, and 30 s at 72°C, then 10 min. at 72°C. The PCR
products were separated on an agarose gel and detected by
staining with ethidium bromide (788 bp β-gal, 200 bp
M37335).
Antiserum generation and assay (ELISA)
For generating antisera, mice were immunized by intra-
peritoneal (i.p.) injection of 50 µg β-gal protein emulsi-
fied in complete Freund's adjuvant (CFA, 50 µl final
volume) and boosted 4 weeks later with 50 µg β-gal, i.p.,
in phosphate buffered saline. β-gal (CAS 9031-11-2) pro-
tein was purchased from Sigma (recombinant, G3153)
and Calbiochem (345788). These preparations were used
interchangeably and no differences were observed. Alter-
natively, mice were immunized with a gene gun. Briefly,
an expression vector encoding β-gal (100 µg, CMV-β-gal,
Clontech, CA) was precipitated with CaCl2  onto gold
beads (21 mg, 2.6 µm diameter, Aldrich or 1 µm BioRad),
which were dried onto plastic tubing (1/8" × 3/32" Tefzel,
Bio-Rad). The tubing was cut (25 × 1 cm) and loaded into
a high pressure gun (Agracetus, Middleton, WI). With a
burst of gas (300 psi), the beads were delivered into the
skin on the backs of mice whose fur had been clipped.
Mice were boosted with a second gene gun immunization
after 6 weeks.
Serum samples were taken before and after immuniza-
tions, as noted in the figures. Blood was allowed to clot at
room temperature then it was placed at 4°C for 2–12 h.
The clots were spun down at 10,000 × g and the sera were
collected and stored frozen at -20°C.
Wells of a 96-well plate (Microtest III, Becton-Dickinson)
were coated with β-gal protein (2 µg/ml PBS, 50 µl/well,
overnight), blocked (50 µl 1% BSA/PBS, 2 h), and rinsed
with wash buffer (0.05% Tween 20, 138 mM NaCl, 2.7
mM KCl, 50 mM Tris, pH 8.0). Sera were diluted in dilu-
tion buffer (1% BSA/PBS) either 1:200 initially and 1:3
serially or 1:1,000 initially and 1:5 serially then added (50
µl). After incubation (2 h), the wells were washed and sec-
ondary antibodies were added (50 µl, 1:2,000 diluted
alkaline phosphatase conjugated goat anti-mouse IgG1 or
IgG2a, ICN Biochemicals). The specificity of these second-
ary antibodies was confirmed in a sandwich ELISA on
plates coated with a capture antibody (goat anti-mouse Fc,
Jackson Immunoresearch) and using the mAbs WT31
(IgG1) and M9144 (IgG2a) as positive and negative con-
trols. After incubation (1 h), wells were washed and sub-
strate was added (50 µl p-nitrophenyl phosphate, Sigma).
After color developed (<1 h), the absorption at 405 nm
wavelength was measured on a plate reader (Bio-Rad).
Antiserum titers were determined from a curve fit to the
data.
T cell culture and analysis (FACS, proliferation, IFN-γ)
Mice were immunized by subcutaneous injection in the
base of the tail with 25 µg of β-gal emulsified in CFA in a
total volume of 50 µl. The draining inguinal lymph nodes
were harvested on day 7. Lymph node cells were cultured
either alone or with irradiated filler cells (0.2 ml, 96-well
plate (Microtest, Falcon) in complete medium (RPMI
1640, 10% FBS, 100 Units/ml penicillin, 100 µg/ml strep-
tomycin, 2.5 mM L-glutamine, 1 mM Sodium pyruvate,
100 µM non-essential amino acids, 50 µM 2-mercaptoeth-
anol, 5 mM HEPES (GIBCO, Grand Island, NY)) with
antigen additions at 10 µg/ml or as noted in the Results.
For flow cytometric analysis, cells from triplicate wells
were harvested, pooled, and incubated with biotin-conju-
gated rat anti-mouse CD25 (clone PC 615.3, Caltag, Burl-
ingame, CA), washed and then incubated with
fluorescein-conjugated streptavidin (Amersham), Quan-
tum Red-conjugated rat anti-mouse CD4 (clone H129.19,
Sigma) and R-Phycoerythrin-conjugated rat-anti-mouse
CD8a (clone 53-6.7, Sigma or Pharmingen) then ana-
lyzed by flow cytometry (FACS Scan, Becton-Dickinson,
CA). For proliferation studies, triplicate wells were pulsed
with  3H-thymidine 16 hours prior to harvesting. For
measurement of secreted IFN-γ, supernatants from tripli-
cate cultures were harvested, centrifuged to remove resid-
ual cells, and frozen until sandwich immunoassay (R & D
Systems, Minneapolis, MN). Replicates supernatants were
assayed individually and the results were averaged. For all
T cell cultures, purified protein derivative (PPD, Mycobac-
terium tuberculosis H37Rv, Mycos Research LLC, FortBMC Immunology 2004, 5 http://www.biomedcentral.com/1471-2172/5/5
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Collins, CO) was used as a positive control and ovalbu-
min (OVA) was used as a negative control. Responses to
OVA were not significantly different from the responses of
unstimulated cultures (data not shown).
Blood vessel analyses
A portion of skin (~4 cm2) and the heart were harvested
from freshly sacrificed mice. Skin sections and the heart
base were placed into neutral buffered formalin (10%,
Sigma) for 5 min. then washed 4 times in PBS. Staining
solution was added (0.25 ml, 1 mg/ml 5-bromo-4-chloro-
3-indolyl-β-D-galactopyranoside (X-gal), 1 mM MgCl2,
10 mM K3Fe(CN)6, 10 mM K4Fe(CN)6 in PBS) and the
reaction proceeded at room temperature overnight. Dig-
ital photographs were taken (DC290, Kodak, Rochester
NY) through a microscope (SMZ1000, Nikon).
Blood vessel morphometry was performed on animals
that were perfusion fixed immediately after sacrifice. Ves-
sels were dissected, embedded in OCT, and flash frozen.
Sections were cut, stained with hematoxalin and eosin or
Elastic van Giesen, and scored under a microscope
(Optiphot2, Nikon).
β-gal vaccinia virus infection
Recombinant vaccinia virus containing the lacZ gene (β-
gal-VV) was generously provided for these studies by Dr.
Nicholas Restifo (NCI, Bethesda, MD). Virus was grown
and titered using HeLa cells. Virus stock was prepared by
scrape harvesting in PBS, freeze thawing three times, and
passing the suspension through a 70 µm sieve. Mice were
infected with 107 PFU (0.25–0.35 ml, i.p.).
Skin transplantation
Donor and recipient mice were anaesthetised (0.2 ml
xylazene/ketamine per 20 g body weight i.p.). Ophthal-
mic balm was applied to protect their eyes. Effective
anaesthesia was tested before proceeding by pinching.
More anaesthetic (~0.05 ml) was administered if the
mouse flinched. Fur was clipped off the upper back and a
full thickness, ~1 cm square patch of skin was cut from the
upper backs. The host skin patch was removed and
replaced with the donor skin patch, which was held in
place by surgical staples. Mice were kept warm and under
observation until they recovered, then single housed until
they were healed (~2 w).
Heart transplantation
Heterotopic vascularized cardiac transplantation was per-
formed as previously described [68]. The donor heart was
arrested by infusion of 0.5 ml of University of Wisconsin
(UW) solution (DuPont, Wilmington, Delaware, USA)
into the inferior vena cava and the aortic root was flushed
with 0.1 ml of UW solution to expel intracoronary blood
thoroughly. The heart was removed from the chest and
placed into UW solution on ice. After the recipient
abdominal aorta and inferior vena cava were isolated, the
donor aorta and pulmonary artery were joined end-to-
side to the recipient aorta and vena cava, respectively,
using 10-0 nylon suture. After the completion of the anas-
tomoses, the abdomen was closed with a single running
suture to all layers. The recipient mouse was then warmed
for a few hours during recovery from anesthesia and had
free access to water and food. The function of the trans-
planted hearts was assessed daily by abdominal palpation
Abbreviations
EC, endothelial cells; HUVEC, human umbilical vein
endothelial cells; β-gal, E. coli β-galactosidase; X-gal, 5-
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Authors' contributions
All authors provided helpful and critical comments. AR
helped plan and perform the cellular assays. YW per-
formed the heterotopic heart transplants. JS performed
the skin transplantation. BM-K assisted in cellular and
molecular assays. WA provided the VWF-lacZ mice. JP and
GT suggested the heart transplantation experiments. DJ
conceived the study and participated in its design and exe-
cution. All authors read and approved the final
manuscript.
Acknowledgements
We thank Dr. Janet Brandsma and Dr. Mark Shlyankevich for their assist-
ance in using the gene gun and Dr. Deepti Pradhan for conducting the plas-
mon resonance affinity assay. We thank Ms. Faiya Wang for her assistance 
in skin transplantation and Ms. Lisa Grass for her assistance in sampling 
mouse sera. We thank Dr. Jun Yu and Dr. William Sessa for their analysis 
of the response to vessel injury. This work was supported by grants from 
the American Heart Association (Heritage Affiliate) and the NIH (HL62188, 
HL51014).
References
1. Pober JS, Cotran RS: The role of endothelial cells in
inflammation. Transplantation 1990, 50:537-544.
2. Austrup F, Vestweber D, Borges E, Löhning M, Bräuer R, Herz U,
Renz H, Hallmann R, Scheffold A, Radbruch A, Hamann A: P- and E-
selectin mediate recruitment of T-helper-1 but not T-
helper-2 cells into inflamed tissues. Nature 1997, 385:81-83.
3. de Waal RM, Bogman MJ, Maass CN, Cornelissen LM, Tax WJ, Koene
RA:  Variable expression of Ia antigens on the vascular
endothelium of mouse skin allografts.  Nature 1983,
303:426-429.
4. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T,
Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P,
Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF,
Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG,
Lindblad AS, Yamaguchi Y  et al.: The Banff 97 working classifica-
tion of renal allograft pathology. Kidney Int 1999, 55:713-723.
5. Ross R: Atherosclerosis – an inflammatory disease. N Engl J
Med 1999, 340:115-126.
6. Ridge JP, Di Rosa F, Matzinger P: A conditioned dendritic cell can
be a temporal bridge between a CD4+ T- helper and a T-
killer cell. Nature 1998, 393:474-478.
7. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR:
Help for cytotoxic-T-cell responses is mediated by CD40
signalling. Nature 1998, 393:478-480.BMC Immunology 2004, 5 http://www.biomedcentral.com/1471-2172/5/5
Page 14 of 15
(page number not for citation purposes)
8. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ: T-
cell help for cytotoxic T lymphocytes is mediated by CD40-
CD40L interactions. Nature 1998, 393:480-483.
9. Marelli-Berg FM, Scott D, Bartok I, Peek E, Dyson J, Lechler RI: Acti-
vated murine endothelial cells have reduced immunogenic-
ity for CD8+ T cells: a mechanism of immunoregulation? J
Immunol 2000, 165:4182-4189.
10. Kosaka H, Surh CD, Sprent J: Stimulation of mature unprimed
CD8+ T cells by semiprofessional antigen- presenting cells in
vivo. J Exp Med 1992, 176:1291-1302.
11. Geppert T, Lipsky P: Antigen presentation by interferon-
gamma-treated endothelial cells and fibroblasts: differential
ability to function as antigen-presenting cells despite compa-
rable Ia expression. J Immunol 1985, 135:3750-3762.
12. Vora M, Yssel H, de Vries J, Karasek M: Antigen presentation by
human dermal microvascular endothelial cells. Immunoreg-
ulatory effect of IFN-γ and IL-10. J Immunol 1994, 152:5734-5741.
13. Briscoe DM, Henault LE, Geehan C, Alexander SI, Lichtman AH:
Human endothelial cell costimulation of T cell IFN-gamma
production. J Immunol 1997, 159:3247-3256.
14. Hirschberg H, Evensen S, Henriksen T, Thorsby E: The human
mixed lymphocyte-endothelium culture interaction.  Trans-
plantation 1975, 19:495-504.
15. Ashida E, Johnson A, Lipsky P: Human Endothelial Cell-Lym-
phocyte Interaction: Endothelial cells fuction as accessory
cells necessary for mitogen-induced human T lymphocyte
activation in vitro. J Clin Invest 1981, 67:1490-1499.
16. Guinan EC, Smith BR, Doukas JT, Miller RA, Pober JS: Vascular
endothelial cells enhance T cell responses by markedly aug-
menting IL-2 concentrations. Cell Immunol 1989, 118:166-177.
17. Hughes C, Savage C, Pober JS: Endothelial cells augment T cell
interleukin 2 production by a contact-dependent mechanism
involving CD2/LFA-3 interaction.  J Exp Med 1990,
171:1453-1467.
18. St. Louis J, Lederer J, Lichtman A: Costimulator deficient antigen
presentation by an endothelial cell line induces a nonprolif-
erative T cell activation response without anergy. J Exp Med
1993, 178:1597-1605.
19. Hancock WW, Sayegh MH, Zheng XG, Peach R, Linsley PS, Turka LA:
Costimulatory function and expression of CD40 ligand,
CD80, and CD86 in vascularized murine cardiac allograft
rejection. Proc Natl Acad Sci U S A 1996, 93:13967-13972.
20. Johnson DR, Hauser IA, Voll RE, Emmrich F: Arterial and venular
endothelial cell costimulation of cytokine secretion by
human T cell clones. J Leukoc Biol 1998, 63:612-619.
21. Karmann K, Min W, Fanslow WC, Pober JS: Activation and
homologous desensitization of human endothelial cells by
CD40 ligand, tumor necrosis factor, and interleukin 1. J Exp
Med 1996, 184:173-182.
22. Khayyamian S, Hutloff A, Buchner K, Grafe M, Henn V, Kroczek RA,
Mages HW: ICOS-ligand, expressed on human endothelial
cells, costimulates Th1 and Th2 cytokine secretion by mem-
ory CD4+ T cells. Proc Natl Acad Sci U S A 2002, 99:6198-6203.
23. Kunitomi A, Hori T, Imura A, Uchiyama T: Vascular endothelial
cells provide T cells with costimulatory signals via the OX40/
gp34 system. J Leukoc Biol 2000, 68:111-118.
24. Ma W, Pober JS: Human endothelial cells effectively costimu-
late cytokine production by, but not differentiation of, naive
CD4+ T cells. J Immunol 1998, 161:2158-2167.
25. Perez VL, Henault L, Lichtman AH: Endothelial antigen presenta-
tion: stimulation of previously activated but not naive TCR-
transgenic mouse T cells. Cell Immunol 1998, 189:31-40.
26. Limmer A, Ohl J, Kurts C, Ljunggren HG, Reiss Y, Groettrup M,
Momburg F, Arnold B, Knolle PA: Efficient presentation of exog-
enous antigen by liver endothelial cells to CD8+ T cells
results in antigen-specific T-cell tolerance.  Nat Med 2000,
6:1348-1354.
27. Kreisel D, Krupnick AS, Gelman AE, Engels FH, Popma SH, Krasinskas
AM, Balsara KR, Szeto WY, Turka LA, Rosengard BR: Non-hemat-
opoietic allograft cells directly activate CD8+ T cells and
trigger acute rejection: an alternative mechanism of
allorecognition. Nat Med 2002, 8:233-239.
28. Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ: The detailed dis-
tribution of HLA-A, B, C antigens in normal human organs.
Transplantation 1984, 38:287-292.
29. Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ: The detailed dis-
tribution of MHC Class II antigens in normal human organs.
Transplantation 1984, 38:293-298.
30. Goes N, Urmson J, Hobart M, Halloran P: The unique role of
interferon-γ in the regulation of MHC expression on arterial
endothelium. Transplantation 1996, 62:1889-1894.
31. Cinamon G, Shinder V, Alon R: Shear forces promote lym-
phocyte migration across vascular endothelium bearing api-
cal chemokines. Nat Immunol 2001, 2:515-522.
32. Cuvelier SL, Patel KD: Shear-dependent eosinophil transmigra-
tion on interleukin 4-stimulated endothelial cells: a role for
endothelium-associated eotaxin-3.  J Exp Med 2001,
194:1699-1709.
33. Salmi M, Tohka S, Jalkanen S: Human vascular adhesion protein-
1 (VAP-1) plays a critical role in lymphocyte-endothelial cell
adhesion cascade under shear. Circ Res 2000, 86:1245-1251.
34. Iezzi G, Karjalainen K, Lanzavecchia A: The duration of antigenic
stimulation determines the fate of naive and effector T cells.
Immunity 1998, 8:89-95.
35. Theopold U, Kohler G: Partial tolerance in beta-galactosidase-
transgenic mice. Eur J Immunol 1990, 20:1311-1316.
36. Borrow P, Cornell JL, Ruppe MD, Mucke L: Immunization-
induced inflammatory infiltration of the central nervous sys-
tem in transgenic mice expressing a microbial antigen in
astrocytes. J Neuroimmunol 1995, 61:133-149.
37. Ludewig B, Freigang S, Jaggi M, Kurrer MO, Pei YC, Vlk L, Odermatt
B, Zinkernagel RM, Hengartner H: Linking immune-mediated
arterial inflammation and cholesterol-induced atherosclero-
sis in a transgenic mouse model. Proc Natl Acad Sci U S A 2000,
97:12752-12757.
38. Morahan G, Allison J, Miller JF: Tolerance of class I histocompat-
ibility antigens expressed extrathymically.  Nature 1989,
339:622-624.
39. Lo D, Freedman J, Hesse S, Brinster RL, Sherman L: Peripheral tol-
erance in transgenic mice: tolerance to class II MHC and
non-MHC transgene antigens. Immunol Rev 1991, 122:87-102.
40. Aird W, Edelberg J, Weiler-Guettler H, Simmons W, Smith T, Rosen-
berg R: Vascular bed-specific expression of an endothelial cell
gene is programmed by the tissue microenvironment. J Cell
Biol 1997, 138:1117-1124.
41. Schlaeger TM, Bartunkova S, Lawitts JA, Teichmann G, Risau W,
Deutsch U, Sato TN: Uniform vascular-endothelial-cell-specific
gene expression in both embryonic and adult transgenic
mice. Proc Natl Acad Sci U S A 1997, 94:3058-3063.
42. Williams RS, Johnston SA, Riedy M, DeVit MJ, McElligott SG, Sanford
JC: Introduction of foreign genes into tissues of living mice by
DNA-coated microprojectiles. Proc Natl Acad Sci U S A 1991,
88:2726-2730.
43. Tang DC, DeVit M, Johnston SA: Genetic immunization is a sim-
ple method for eliciting an immune response. Nature 1992,
356:152-154.
44. Corr M, Lee DJ, Carson DA, Tighe H: Gene vaccination with
naked plasmid DNA: mechanism of CTL priming. J Exp Med
1996, 184:1555-1560.
45. Manca F, Kunkl A, Fenoglio D, Fowler A, Sercarz E, Celada F: Con-
straints in T-B cooperation related to epitope topology on E.
coli beta-galactosidase. I. The fine specificity of T cells dic-
tates the fine specificity of antibodies directed to conforma-
tion-dependent determinants. Eur J Immunol 1985, 15:345-350.
46. Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME: Meas-
urements of the true affinity constant in solution of antigen-
antibody complexes by enzyme-linked immunosorbent
assay. J Immunol Methods 1985, 77:305-319.
47. de Visser KE, Cordaro TA, Kioussis D, Haanen JB, Schumacher TN,
Kruisbeek AM: Tracing and characterization of the low-avidity
self-specific T cell repertoire. Eur J Immunol 2000, 30:1458-1468.
48. Tellides G, Tereb DA, Kirkiles-Smith NC, Kim RW, Wilson JH,
Schechner JS, Lorber MI, Pober JS: Interferon-gamma elicits arte-
riosclerosis in the absence of leukocytes.  Nature 2000,
403:207-211.
49. Benoist C, Mathis D: Autoimmunity provoked by infection:
how good is the case for T cell epitope mimicry? Nat Immunol
2001, 2:797-801.
50. Chisari FV, Ferrari C: Hepatitis B virus immunopathogenesis.
Annu Rev Immunol 1995, 13:29-60.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Immunology 2004, 5 http://www.biomedcentral.com/1471-2172/5/5
Page 15 of 15
(page number not for citation purposes)
51. Tindle RW: Peripheral T-cell tolerance defined through trans-
genic mouse studies. Autoimmunity 2001, 33:135-149.
52. Pober J, Orosz C, Rose M, Savage C: Can graft endothelial cells
initiate a host anti-graft immune response?  Transplantation
1996, 61:343-349.
53. Silverstein AM: The History of Immunology. In: Fundamental
Immunology 4th edition. Edited by: Paul WE. Philadelphia: Lippincott-
Raven; 1999:19-35. 
54. Schwartz R: Immunological Tolerance. In: Fundamental Immunol-
ogy 4th edition. Edited by: Paul WE. Philadelphia: Lippencott-Raven Press;
1999:701-739. 
55. Risau W, Engelhardt B, Wekerle H: Immune function of the
blood-brain barrier: incomplete presentation of protein
(auto-)antigens by rat brain microvascular endothelium in
vitro. J Cell Biol 1990, 110:1757-1766.
56. Dengler TJ, Johnson DR, Pober JS: Human Vascular Endothelial
Cells Stimulate a Lower Frequency of Alloreactive CD8(+)
Pre-CTL and Induce Less Clonal Expansion than Matching B
Lymphoblastoid Cells: Development of a Novel Limiting
Dilution Analysis Method Based on CFSE Labeling of
Lymphocytes. J Immunol 2001, 166:3846-3854.
57. Biedermann BC, Pober JS: Human vascular endothelial cells
favor clonal expansion of unusual alloreactive CTL. J Immunol
1999, 162:7022-7030.
58. Nugent CT, Morgan DJ, Biggs JA, Ko A, Pilip IM, Pamer EG, Sherman
LA: Characterization of CD8+ T lymphocytes that persist
after peripheral tolerance to a self antigen expressed in the
pancreas. J Immunol 2000, 164:191-200.
59. Ma H, Ke Y, Li Q, Kapp JA: Bovine and human insulin activate
CD8+-autoreactive CTL expressing both type 1 and type 2
cytokines in C57BL/6 mice. J Immunol 2000, 164:86-92.
60. Jones-Youngblood SL, Wieties K, Forman J, Hammer RE: Effect of
the expression of a hepatocyte-specific MHC molecule in
transgenic mice on T cell tolerance.  J Immunol 1990,
144:1187-1195.
61. Wieties K, Hammer RE, Jones-Youngblood S, Forman J: Peripheral
tolerance in mice expressing a liver-specific class I molecule:
inactivation/deletion of a T-cell subpopulation. Proc Natl Acad
Sci U S A 1990, 87:6604-6608.
62. Salomon B, Bluestone JA: Complexities of CD28/B7: CTLA-4
costimulatory pathways in autoimmunity and
transplantation. Annu Rev Immunol 2001, 19:225-252.
63. Walker L, Ausube L, Chodos A, Bekarian N, Abbas A: CTLA-4 Dif-
ferentially Regulates T Cell Responses to Endogenous Tissue
Protein Versus Exogenous Immunogen.  J Immunol 2002,
169:6202-6209.
64. Maeda H, Fujimoto S, Greene MI: Suppressor T cells regulate the
nonanergic cell population that remains after peripheral tol-
erance is induced to the Mls-1 antigen in T cell receptor
Vbeta 8.1 transgenic mice.  Proc Natl Acad Sci U S A 2000,
97:13257-13262.
65. Adelstein S, Pritchard-Briscoe H, Anderson TA, Crosbie J, Gammon
G, Loblay RH, Basten A, Goodnow CC: Induction of self-toler-
ance in T cells but not B cells of transgenic mice expressing
little self antigen. Science 1991, 251:1223-1225.
66. Viola A, Lanzavecchia A: T cell activation determined by T cell
receptor number and tunable thresholds.  Science 1996,
273:104-106.
67. Gimmi C, Freeman G, Gribben J, Gray G, Nadler L: Human T-cell
clonal anergy is induced by antigen presentation in the
absence of B7 costimulation.  Proc Natl Acad Sci (USA) 1993,
90:6586-6590.
68. Wang Y, Qin L, Bai Y, Bielinska AU, Kukowska-Latallo JF, JRB  Jr, Bro-
mberg JS: DNA/dendrimer complexes mediate gene transfer
into murine cardiac transplants ex vivo. Molecular Therapy 2000,
1:602-608.